D-1545-2020 Class II Terminated
FDA drug recall D-1545-2020 was initiated by Hetero Labs Limited (Unit V) on Aug 6, 2020 and is designated Class II. Reason for recall: Failed Tablet/Capsule Specification; complaint of bulging tablet The recall status is terminated (terminated Jan 24, 2022). Affected quantity: 43,512 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Sep 2, 2020
- Initiation Date
- Aug 6, 2020
- Termination Date
- Jan 24, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 43,512 bottles
Product description
Losartan Potassium Tablets USP, 50 mg, 90 count bottles, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ by Hetero Labs, Limited, Mahabubragar, India
Reason for recall
Failed Tablet/Capsule Specification; complaint of bulging tablet
Distribution pattern
Product was distributed to major wholesalers/distributors throughout the United States.
Code information
Batch # LOA19357A, exp. date 09/2021
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1545-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026